Welcome to CDC stacks |
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
A Public Health Approach to the Prevention of Inhibitors in Hemophilia
  • Published Date:
    Sep 19 2014
  • Source:
    Am J Prev Med. 47(5):669-673.
Filetype[PDF-70.61 KB]


Details:
No Related Documents.
You May Also Like:
  1. Improving the performance of factor VIII inhibitor tests in hemophilia A
    Personal Author:
    Miller, Connie H.
    Published Date:
    Sep 28 2015
    Source:
    Thromb Res. 136(6):1047-1048.
    File Type:
    Filetype[PDF - 41.93 KB]
  2. Achievements, challenges and unmet needs for haemophilia patients with inhibitors
    Personal Author:
    DARGAUD, Y.; PAVLOVA, A.; LACROIX-DESMAZES, S.; FISCHER, K.; SOUCIE, M.; CLAEYSSENS, S.; SCOTT, D.W.; d’OIRON, R.; LAVIGNE-LISSALDE, G.; KENET, G.; ETTINGSHAUSEN, C. ESCURIOLA; BOREL-DERLON, A.; LAMBERT, T.; PASTA, G.; NÉGRIER, C.;
    Published Date:
    Jan 2016
    Source:
    Haemophilia. 22(Suppl 1):1-24.
    Description:
    Over the past 20 years, there have been many advances in haemophilia treatment that have allowed patients to take greater control of their disease. However, the development of factor VIII (FVIII) inhibitors is the greatest complication of the disease...
    File Type:
    Filetype[PDF - 638.38 KB]
  3. National surveillance for hemophilia inhibitors in the United States: Summary report of an expert meeting
    Personal Author:
    Soucie, J. Michael; Miller, Connie H.; Kelly, Fiona M.; Aschman, Diane; DiMichele, Donna; Konkle, Barbara A.; Kulkarni, Roshni; Monahan, Paul E.;
    Published Date:
    Apr 10 2014
    Source:
    Am J Hematol. 2014; 89(6):621-625.
    Description:
    On March 12, 2012, the Centers for Disease Control and Prevention (CDC) held a meeting of its partners in hemophilia treatment, community-based organizations, industry, and government to review data and discuss implementation issues relevant to plann...
    File Type:
    Filetype[PDF - 122.10 KB]
  4. Origins and organization of the NHLBI State of the Science Workshop: Generating a national blueprint for future research on factor VIII inhibitors
    Personal Author:
    Sabatino, Denise E.; Pipe, Steven W.; Nugent, Diane J.; Soucie, J. Michael; Hooper, W. Craig; Hoots, W. Keith; DiMichele, Donna M.;
    Published Date:
    Jul 2019
    Source:
    Haemophilia. 25(4):575-580
    Description:
    IntroductionThe major complication of protein replacement therapy for haemophilia A is the development of anti-FVIII antibodies or inhibitors that occur in 25%−30% of persons with severe haemophilia A. Alternative therapeutics such as bypassing age...
    File Type:
    Filetype[PDF - 66.27 KB]
  5. Prevalent Inhibitors in Hemophilia B Subjects Enrolled in the Universal Data Collection Database
    Personal Author:
    Puetz, John; Soucie, J. Michael; Kempton, Christine L.; Monahan, Paul E.;
    Corporate Authors:
    Hemophilia Treatment Center Network (HTCN) Investigators
    Published Date:
    Jul 16 2013
    Source:
    Haemophilia. 20(1):25-31
    Description:
    BackgroundSeveral risk factors for inhibitors have recently been described for hemophilia A. It has been assumed that similar risk factors are also relevant for hemophilia B, but there is limited data to confirm this notion.ObjectivesTo determine the...
    File Type:
    Filetype[PDF - 210.14 KB]